Health Canada Authorizes Lilly's Foundayo Pill for Weight Management and Type 2 Diabetes, With Pharmacy Supply Expected in January
Health Canada authorized Foundayo (orforglipron) on November 13 for adults with obesity and for overweight adults with at least one weight-related condition such as high blood pressure or sleep apnea, as well as for type 2 diabetes, The Canadian Press reported. A Lilly spokesperson said the company expects the daily pills in pharmacies in January. Novo Nordisk's Wegovy pill is still awaiting Health Canada approval, and endocrinologist Dr. Ehud Ur said he is waiting for trial results on whether orforglipron protects the heart, as semaglutide and tirzepatide do.